Related Experiment Video

Updated: Apr 27, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K

TYRO3 as a potential therapeutic target in breast cancer

Roudy Chiminch Ekyalongo1, Toru Mukohara2, Yohei Funakoshi1

  • 1Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Anticancer Research
|July 2, 2014
PubMed
Abstract

Insights

TYRO3 is a promising therapeutic target for breast cancer, especially luminal-type. Knocking down TYRO3 significantly inhibited proliferation in luminal and HER2-type cells but not triple-negative cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Breast cancer comprises diverse subtypes with varying therapeutic responses.
  • TYRO3, a receptor tyrosine kinase, plays roles in cell survival and proliferation.
  • Identifying novel therapeutic targets is crucial for improving breast cancer treatment outcomes.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting TYRO3 in different breast cancer subtypes.
  • To evaluate the impact of TYRO3 inhibition on cancer cell proliferation and signaling pathways.

Main Methods:

  • Utilized small interfering RNA (siRNA) to knockdown TYRO3 expression in various breast cancer cell lines.
  • Assessed effects on cell proliferation, cell-cycle distribution, and key signaling molecules (ERK1/2, STAT3, cyclin D1).
  • Compared responses across estrogen receptor (ER)-positive/HER2-non-amplified (luminal), ER-negative/HER2-amplified (HER2), and ER-negative/HER2-non-amplified (triple-negative) subtypes.

Main Results:

  • TYRO3 knockdown markedly suppressed proliferation in luminal-type cells and, to a lesser extent, in HER2-type cells.
  • No significant proliferation inhibition was observed in triple-negative breast cancer cells.
  • Proliferation suppression in luminal cells correlated with G0-G1/S cell-cycle arrest and reduced ERK1/2/STAT3 phosphorylation and cyclin D1 levels.

Conclusions:

  • TYRO3 represents a potential therapeutic target for breast cancer treatment.
  • The efficacy of TYRO3 inhibition is most pronounced in luminal-type breast cancer.
  • Further research into TYRO3-targeted therapies for specific breast cancer subtypes is warranted.
Keywords:
Breast cancerTYRO3luminal-typesiRNAtargeted therapy

More Related Videos

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.8K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K